Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression. View All News

Oct 31, 2024 · Syros did not recognize revenue in the third quarter of 2024, as compared to $3.8 million for the third quarter of 2023. The decrease reflects the termination of Syros’ collaboration agreement with Pfizer.

Tamibarotene (formerly SY-1425) is a first-in-class selective retinoic acid receptor alpha (RARα) agonist that is currently in a Phase 2 clinical trial in a genomically defined subset of AML patients, including those with relapsed or refractory AML.

On January 6, 2025, Syros Pharmaceuticals, Inc. (“Syros”) received deficiency letters (the “Notices”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying Syros that:

Oct 24, 2024 · Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk ...

Jan 9, 2023 · CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023.

Dec 12, 2022 · Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches.

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression

Syros is driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, and we aim to develop new standards of care for the frontline treatment of patients with hematologic malignancies.

May 25, 2023 · Syros’ Phase 1/1b trial of SY-5609 is a multi-center, open-label study, consisting of two parts: Part 1 is a dose escalation study, evaluating single agent SY-5609 in patients with select advanced solid tumors and in combination with fulvestrant in HR+ breast cancer.